BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, Hamzeh FM. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. 2012;56:1651-1660. [PMID: 22610658 DOI: 10.1002/hep.25842] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Stahmeyer JT, Krauth C, Bert F, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D, Mauss S, Rossol S. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial. J Viral Hepat 2016;23:105-15. [PMID: 26411532 DOI: 10.1111/jvh.12471] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
2 Estes C, Abdel-Kareem M, Abdel-Razek W, Abdel-Sameea E, Abuzeid M, Gomaa A, Osman W, Razavi H, Zaghla H, Waked I. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther. 2015;42:696-706. [PMID: 26202593 DOI: 10.1111/apt.13316] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
3 Vergara M, Miquel M, Vela E, Cleries M, Pontes C, Prat A, Rué M. Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents. J Viral Hepat 2021;28:728-38. [PMID: 33555102 DOI: 10.1111/jvh.13479] [Reference Citation Analysis]
4 Perrone V, Sangiorgi D, Buda S, Degli Esposti L. Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting. Clinicoecon Outcomes Res 2016;8:591-7. [PMID: 27789966 DOI: 10.2147/CEOR.S108288] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Mazur WP. Management of Hepatitis C in Delaware Prisons: : Approaching Microenvironmental Eradication. Dela J Public Health 2019;5:20-7. [PMID: 34467026 DOI: 10.32481/djph.2019.05.006] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Gordon S, Lee J, Smith N, Dieterich D. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States. Expert Rev Pharmacoecon Outcomes Res 2020;20:251-7. [PMID: 31204882 DOI: 10.1080/14737167.2019.1629291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Suraweera D, Jimenez M, Viramontes M, Jamal N, Grotts J, Elashoff D, Lee EW, Saab S. Age-related Morbidity and Mortality After Transjugular Intrahepatic Portosystemic Shunts. Journal of Clinical Gastroenterology 2017;51:360-3. [DOI: 10.1097/mcg.0000000000000541] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
8 Puenpatom A, Hull M, McPheeters J, Schwebke K. Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States. Infect Dis Ther 2017;6:423-33. [PMID: 28677020 DOI: 10.1007/s40121-017-0163-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
9 Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis. 2014;46 Suppl 5:S186-S196. [PMID: 25458773 DOI: 10.1016/j.dld.2014.09.025] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
10 Shearer JE, Gonzalez JJ, Min T, Parker R, Jones R, Su GL, Tapper EB, Rowe IA. Systematic review: development of a consensus code set to identify cirrhosis in electronic health records. Aliment Pharmacol Ther 2022. [PMID: 35166399 DOI: 10.1111/apt.16806] [Reference Citation Analysis]
11 Dimitrova M, Pavlov K, Mitov K, Genov J, Petrova GI. Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria. Front Med (Lausanne) 2017;4:125. [PMID: 28824914 DOI: 10.3389/fmed.2017.00125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
12 Ti L, Ng M, Awendila L, Carrieri PM. Hepatitis C virus infection and hospital-related outcomes: a systematic review protocol. BMJ Open 2018;8:e021118. [PMID: 29903795 DOI: 10.1136/bmjopen-2017-021118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Rein DB, Borton J, Liffmann DK, Wittenborn JS. The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics: Rein et al. Hepatology 2016;63:1135-44. [DOI: 10.1002/hep.28430] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
14 Sussman NL, Remien CH, Kanwal F. The end of hepatitis C. Clin Gastroenterol Hepatol 2014;12:533-6. [PMID: 24480676 DOI: 10.1016/j.cgh.2014.01.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
15 Kieran JA, Norris S, O'Leary A, Walsh C, Merriman R, Houlihan D, McCormick PA, McKiernan S, Bergin C, Barry M. Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study. BMC Infect Dis. 2015;15:471. [PMID: 26503519 DOI: 10.1186/s12879-015-1208-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
16 Schumock GT, Li EC, Suda KJ, Matusiak LM, Hunkler RJ, Vermeulen LC, Hoffman JM. National trends in prescription drug expenditures and projections for 2014. American Journal of Health-System Pharmacy 2014;71:482-99. [DOI: 10.2146/ajhp130767] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
17 Alvarez KJ, Befus M, Herzig CT, Larson E. Prevalence and correlates of hepatitis C virus infection among inmates at two New York State correctional facilities. J Infect Public Health 2014;7:517-21. [PMID: 25182508 DOI: 10.1016/j.jiph.2014.07.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
18 Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40:657-75. [PMID: 25065960 DOI: 10.1111/apt.12871] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
19 Saab S, Jackson C, Nieto J, Francois F. Hepatitis C in African Americans. Am J Gastroenterol 2014;109:1576-84; quiz 1575, 1585. [PMID: 25178700 DOI: 10.1038/ajg.2014.243] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
20 Batsaikhan B, Huang C, Yeh M, Huang C, Liang P, Hsieh M, Huang J, Yu M, Chuang W, Lee J, Lee P, Dai C. Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients: Cryoglobulinemia and liver fibrosis in CHC. Journal of Gastroenterology and Hepatology 2018;33:1897-903. [DOI: 10.1111/jgh.14275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chirikov VV, Shaya FT, Mullins CD, dosReis S, Onukwugha E, Howell CD. Determinants of quality of care and treatment initiation in Medicare disabled patients with chronic hepatitis C. Expert Rev Gastroenterol Hepatol 2015;9:1447-62. [PMID: 26524244 DOI: 10.1586/17474124.2015.1095087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: Treatment of difficult to treat patients. World J Hepatol 2015; 7(15): 1953-1963 [PMID: 26244069 DOI: 10.4254/wjh.v7.i15.1953] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
23 Bennett H, Gordon J, Jones B, Ward T, Webster S, Kalsekar A, Yuan Y, Brenner M, Mcewan P. Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. Eur J Health Econ 2017;18:1001-11. [DOI: 10.1007/s10198-016-0844-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
24 Haley SJ, Kreek MJ. A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act. Am J Public Health 2015;105:457-63. [PMID: 25602859 DOI: 10.2105/AJPH.2014.302327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
25 Poonsapaya JM, Einodshofer M, Kirkham HS, Glover P, DuChane J. New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison. Cost Eff Resour Alloc 2015;13:17. [PMID: 26445564 DOI: 10.1186/s12962-015-0043-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
26 Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, Pasulo L. Management of hepatitis C infection before and after liver transplantation. World J Gastroenterol 2015; 21(15): 4447-4456 [PMID: 25914454 DOI: 10.3748/wjg.v21.i15.4447] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
27 Pascual-Argente N, Puig-Junoy J, Llagostera-Punzano A. Non-healthcare costs of hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol 2018;12:19-30. [PMID: 28844170 DOI: 10.1080/17474124.2017.1373016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
28 Cachay ER, Hill L, Ballard C, Colwell B, Torriani F, Wyles D, Mathews WC. Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model. AIDS Res Ther 2013;10:9. [PMID: 23537147 DOI: 10.1186/1742-6405-10-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
29 Turri JAO, Decimoni TC, Ferreira LA, Diniz MA, Haddad LBDP, Campolina AG. Higher MELD score increases the overall cost on the waiting list for liver transplantation: a micro-costing analysis based study. Arq Gastroenterol 2017;54:238-45. [DOI: 10.1590/s0004-2803.201700000-35] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
30 Rogal SS, Winger D, Bielefeldt K, Rollman BL, Szigethy E. Healthcare utilization in chronic liver disease: the importance of pain and prescription opioid use. Liver Int. 2013;33:1497-1503. [PMID: 23758842 DOI: 10.1111/liv.12215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
31 Niu B, Forde KA, Goldberg DS. Coding algorithms for identifying patients with cirrhosis and hepatitis B or C virus using administrative data. Pharmacoepidemiol Drug Saf 2015;24:107-11. [PMID: 25335773 DOI: 10.1002/pds.3721] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
32 Malsam R, Nienhaus A. Occupational Infections among Dental Health Workers in Germany-14-Year Time Trends. Int J Environ Res Public Health 2021;18:10128. [PMID: 34639430 DOI: 10.3390/ijerph181910128] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Luhnen M, Waffenschmidt S, Gerber-Grote A, Hanke G. Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic Review. Appl Health Econ Health Policy. 2016;14:527-543. [PMID: 27329481 DOI: 10.1007/s40258-016-0253-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
34 Stepanova M, De Avila L, Afendy M, Younossi I, Pham H, Cable R, Younossi ZM. Direct and Indirect Economic Burden of Chronic Liver Disease in the United States. Clinical Gastroenterology and Hepatology 2017;15:759-766.e5. [DOI: 10.1016/j.cgh.2016.07.020] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 12.4] [Reference Citation Analysis]
35 Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. Medicine (Baltimore) 2016;95:e5048. [PMID: 27741116 DOI: 10.1097/MD.0000000000005048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 5.4] [Reference Citation Analysis]
36 Satoskar R, Reau N. Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force. Hepatology 2013;58:422-7. [PMID: 23460345 DOI: 10.1002/hep.26349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
37 Carrozzo M. Hepatitis C virus: a silent killer relevant to dentistry. Oral Dis 2014;20:425-9. [PMID: 24666473 DOI: 10.1111/odi.12240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Papatheodoridi Μ, Dalekos GN, Goulis J, Manolakopoulos S, Triantos C, Zachou K, Koukoufiki A, Κourikou Α, Ζisimopoulos Κ, Τsoulas C, Papatheodoridis GV. Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. Ann Gastroenterol 2017;30:542-9. [PMID: 28845110 DOI: 10.20524/aog.2017.0170] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
39 Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ, Volk ML, Blow FC, Lok ASF. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018;68:872-882. [PMID: 29579356 DOI: 10.1002/hep.29887] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 20.8] [Reference Citation Analysis]
40 Park H, Wang W, Henry L, Nelson DR. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States. Hepatology 2019;69:1032-45. [PMID: 30289989 DOI: 10.1002/hep.30303] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
41 Kelly EM, James PD, Murthy S, Antonova L, Wong F, Shaw-Stiffel T, Chalifoux M, Salim M, Tanuseputro P. Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. Clin Gastroenterol Hepatol 2019;17:2339-2346.e1. [PMID: 30743007 DOI: 10.1016/j.cgh.2019.01.046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
42 Klebanoff MJ, Corey KE, Samur S, Choi JG, Kaplan LM, Chhatwal J, Hur C. Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. JAMA Netw Open 2019;2:e190047. [PMID: 30794300 DOI: 10.1001/jamanetworkopen.2019.0047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
43 Wild SH, Morling JR, McAllister DA, Kerssens J, Fischbacher C, Parkes J, Roderick PJ, Sattar N, Byrne CD. Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. J Hepatol. 2016;64:1358-1364. [PMID: 26812073 DOI: 10.1016/j.jhep.2016.01.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
44 Sarpel D, Baichoo E, Dieterich DT. Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening. Expert Review of Anti-infective Therapy 2016;14:511-21. [DOI: 10.1586/14787210.2016.1174066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
45 Schwarzinger M, Rehm J, Mallet V. "Who killed JR": Chronic hepatitis C or alcohol use disorders? J Hepatol 2018;68:1098-9. [PMID: 29294316 DOI: 10.1016/j.jhep.2017.11.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
46 Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D, Foster G, Gilmore I, Hickman M, Hudson M, Kelly D, Langford A, Lombard M, Longworth L, Martin N, Moriarty K, Newsome P, O'Grady J, Pryke R, Rutter H, Ryder S, Sheron N, Smith T. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. 2014;384:1953-1997. [PMID: 25433429 DOI: 10.1016/s0140-6736(14)61838-9] [Cited by in Crossref: 322] [Cited by in F6Publishing: 151] [Article Influence: 46.0] [Reference Citation Analysis]
47 Westermann C, Dulon M, Wendeler D, Nienhaus A. Hepatitis C among healthcare personnel: secondary data analyses of costs and trends for hepatitis C infections with occupational causes. J Occup Med Toxicol 2016;11:52. [PMID: 27904646 DOI: 10.1186/s12995-016-0142-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
48 Barritt AS, Jhaveri R. Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV. Curr HIV/AIDS Rep 2018;15:155-61. [DOI: 10.1007/s11904-018-0386-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
49 Khemichian S, Terrault NA. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease. Semin Thromb Hemost. 2020;46:682-692. [PMID: 32820479 DOI: 10.1055/s-0040-1715451] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
50 Moorman AC, Xing J, Ko S, Rupp LB, Xu F, Gordon SC, Lu M, Spradling PR, Teshale EH, Boscarino JA, Vijayadeva V, Schmidt MA, Holmberg SD; CHeCS Investigators. Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): Missed opportunities for intervention. Hepatology 2015;61:1479-84. [PMID: 25131217 DOI: 10.1002/hep.27365] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
51 Mankal PK, Abed J, Aristy JD, Munot K, Suneja U, Engelson ES, Kotler DP. Relative effects of heavy alcohol use and hepatitis C in decompensated chronic liver disease in a hospital inpatient population. Am J Drug Alcohol Abuse 2015;41:177-82. [PMID: 25320839 DOI: 10.3109/00952990.2014.964358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
52 Gani F, Canner JK, Pawlik TM. Assessing coding practices for gastrointestinal surgery over time in the United States. Surgery 2018;164:530-8. [PMID: 29853192 DOI: 10.1016/j.surg.2018.04.021] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Goolsby Hunter A, Rosenblatt L, Patel C, Blauer-Peterson C, Anduze-Faris B. Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype. Curr Med Res Opin 2017;33:829-36. [PMID: 28128648 DOI: 10.1080/03007995.2017.1288613] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
54 Olmedo DB, Cader SA, Porto LC. IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors. J Med Virol 2015;87:1702-15. [PMID: 25970604 DOI: 10.1002/jmv.24227] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
55 Chen Y, Ji H, Shao J, Jia Y, Bao Q, Zhu J, Zhang L, Shen Y. Different Hepatitis C Virus Infection Statuses Show a Significant Risk of Developing Type 2 Diabetes Mellitus: A Network Meta-Analysis. Dig Dis Sci. 2020;65:1940-1950. [PMID: 31758432 DOI: 10.1007/s10620-019-05918-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
56 Younossi ZM, Otgonsuren M, Henry L, Arsalla Z, Stepnaova M, Mishra A, Venkatesan C, Hunt S. Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States. J Viral Hepat. 2015;22:137-145. [PMID: 24813350 DOI: 10.1111/jvh.12262] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
57 Akpo EI, Sbarigia U, Wan G, Kleintjens J. Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients. Drugs R D 2015;15:335-49. [PMID: 26416653 DOI: 10.1007/s40268-015-0109-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
58 Gordon SC, Hamzeh FM, Pockros PJ, Hoop RS, Buikema AR, Korner EJ, Terrault NA. Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther 2013;38:784-93. [PMID: 23981040 DOI: 10.1111/apt.12454] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
59 Xu F, Moorman AC, Tong X, Gordon SC, Rupp LB, Lu M, Teshale EH, Spradling PR, Boscarino JA, Trinacty CM, Schmidt MA, Holmberg SD; Chronic Hepatitis Cohort Study (CHeCS) Investigators, Holmberg SD, Teshale EH, Spradling PR, Moorman AC, Xing J, Tong X, Xu F, Gordon SC, Nerenz DR, Lu M, Lamerato L, Wang Y, Rupp LB, Akkerman N, Oja-Tebbe N, Zhang T, Li J, Sitarik A, Larkin D, Boscarino JA, Daar ZS, Curry PJ, Smith RE, Vijayadeva V, Parker JV, Schmidt MA, Donald JL, Keast EM. All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus. Clin Infect Dis. 2016;62:289-297. [PMID: 26417034 DOI: 10.1093/cid/civ860] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
60 Buti M, Domínguez-Hernández R, Oyagüez I, Casado MÁ. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis]. Gastroenterol Hepatol 2016;39:449-57. [PMID: 27084669 DOI: 10.1016/j.gastrohep.2016.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
61 Parikh ND, Singal AG, Hutton DW, Tapper EB. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. Am J Gastroenterol 2020;115:1642-9. [PMID: 32530829 DOI: 10.14309/ajg.0000000000000715] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
62 Lu M, Chacra W, Rabin D, Rupp LB, Trudeau S, Li J, Gordon SC. Validity of an automated algorithm using diagnosis and procedure codes to identify decompensated cirrhosis using electronic health records. Clin Epidemiol 2017;9:369-76. [PMID: 28744162 DOI: 10.2147/CLEP.S136134] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
63 Smyth D, Webster D. Hepatitis C: pay now or pay later? Future Virology 2015;10:1285-90. [DOI: 10.2217/fvl.15.104] [Reference Citation Analysis]
64 Gordon SC, Lamerato LE, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale E, Xu F, Boscarino JA, Vijayadeva V, Schmidt MA, Oja-Tebbe N, Lu M. Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. Am J Gastroenterol 2015;110:1169-77; quiz 1178. [PMID: 26215529 DOI: 10.1038/ajg.2015.203] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
65 Henkle E, Lu M, Rupp LB, Boscarino JA, Vijayadeva V, Schmidt MA, Gordon SC; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Hepatitis A and B immunity and vaccination in chronic hepatitis B and C patients in a large United States cohort. Clin Infect Dis 2015;60:514-22. [PMID: 25371489 DOI: 10.1093/cid/ciu879] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
66 Qureshi N, Tadesse M, Tran N, Henderson S. Establishing an Epidemiologic Profile of Hepatitis C Virus Infection at the Los Angeles County Jail. Public Health Rep 2021;136:726-35. [PMID: 33602004 DOI: 10.1177/0033354920988610] [Reference Citation Analysis]
67 Younossi ZM, Kanwal F, Saab S, Brown KA, El-Serag HB, Kim WR, Ahmed A, Kugelmas M, Gordon SC. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39:518-531. [PMID: 24461160 DOI: 10.1111/apt.12625] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 11.8] [Reference Citation Analysis]
68 Lu M, Li J, Rupp LB, Zhou Y, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Daida YG, Schmidt MA, Trudeau S, Gordon SC. Changing trends in complications of chronic hepatitis C. Liver Int 2018;38:239-47. [PMID: 28636782 DOI: 10.1111/liv.13501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
69 Otgonsuren M, Henry L, Hunt S, Venkatesan C, Mishra A, Younossi ZM. Resource Utilization and Survival Among Medicare Patients with Advanced Liver Disease. Dig Dis Sci 2015;60:320-32. [DOI: 10.1007/s10620-014-3318-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
70 Stahmeyer JT, Rossol S, Bert F, Antoni C, Demir M, Hinrichsen H, Hüppe D, Teuber G, Wiebner B, Wedemeyer H, Krauth C. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis. Eur J Gastroenterol Hepatol 2014;26:1278-85. [PMID: 25144493 DOI: 10.1097/MEG.0000000000000181] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
71 Hill LA, Delmonte RJ, Andrews B, Richards L, Soto R, Collier S, Kuo A, Cachay E. Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis. Eur J Gastroenterol Hepatol 2018;30:1378-83. [PMID: 29975243 DOI: 10.1097/MEG.0000000000001195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
72 Yin S, Barker L, Teshale EH, Jiles RB. Rising Trends in Emergency Department Visits Associated With Hepatitis C Virus Infection in the United States, 2006-2014. Public Health Rep. 2019;134:685-694. [PMID: 31577517 DOI: 10.1177/0033354919878437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
73 Büsch K, Hansson F, Holton M, Lagging M, Westin J, Kövamees J, Sällberg M, Söderholm J. Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study. BMJ Open 2020;10:e035996. [PMID: 32878754 DOI: 10.1136/bmjopen-2019-035996] [Reference Citation Analysis]
74 Chirapongsathorn S, Poovorawan K, Soonthornworasiri N, Pan-Ngum W, Chaiprasert A, Phaosawasdi K, Treeprasertsuk S. Health care burden and mortality of acute on chronic liver failure in Thailand: a nationwide population-based cohort study. BMC Health Serv Res 2022;22:156. [PMID: 35125103 DOI: 10.1186/s12913-022-07574-6] [Reference Citation Analysis]
75 Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis 2013;56:1382-93. [PMID: 23392392 DOI: 10.1093/cid/cit069] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
76 Younossi ZM, Stepanova M, Nader F, Henry L. Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens. J Am Geriatr Soc 2016;64:386-93. [PMID: 26825683 DOI: 10.1111/jgs.13928] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
77 Zhou HY, Liu S, Zheng SJ, Peng XX, Chen Y, Duan C, Zheng QF, Wang Z, Duan ZP. Coverage of different health insurance programs and medical costs associated with chronic hepatitis C infection in mainland China: a cross-sectional survey in 20 provinces. Hepatol Med Policy 2016;1:7. [PMID: 30288311 DOI: 10.1186/s41124-016-0008-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Ward T, Gordon J, Jones B, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P. Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease. Clin Drug Investig 2017;37:61-70. [PMID: 27587071 DOI: 10.1007/s40261-016-0458-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]